FDA backs Tarix Orphan’s potential DMD treatment

Cambridge, Mass.-based Tarix Orphan, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, has received the FDA’s Fast Track Designation for TXA127 (angiotensin 1-7) to reduce skeletal muscle damage and fibrosis and thereby improve muscle strength in Duchenne Muscular Dystrophy (DMD) patients.

[Read More]

The Pulse

The Pulse on Technology by Ashley Tointon

Choosing to participate in a clinical trial is a big decision that should be weighed carefully. According to the Center for Information and Study on Clinical Research Participation (CISCRP), fewer than 4% of all U.S. physicians participate in clinical trials and only 7% of Americans say their doctors have ever suggested that they participate in a clinical study.

[Read More]

Clinical Intelligence

Awards & Advancement